IRWD
Ironwood Pharmaceuticals, Inc.
NasdaqGSUSDEQUITY
DELAYED
Last price
4.31
▲ 0.17 (4.11%)
MARKET · —
Price
Open
4.03
Prev close
4.14
Day high
4.30
Day low
4.19
Volume
2.21M
Market cap
—
P/E (TTM)
—
52W range
1.01 – 5.78
Trailing performance
Returnvs SPY
1W
-0.46%
+0.9%
1M
+13.19%
+9.5%
3M
+11.43%
+8.3%
6M
+8.33%
-2.7%
YTD
+27.30%
+15.0%
1Y
+290.00%
+270.0%
3Y
-56.05%
-130.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
4.25
+1.36% from price
SMA 20
4.16
+3.11% from price
SMA 50
4.06
+5.54% from price
SMA 100
3.96
+8.85% from price
SMA 200
3.85
+11.34% from price
EMA 12
4.24
+1.74% from price
EMA 26
4.16
+3.58% from price
EMA 50
4.07
+5.79% from price
RSI (14)
53.5
Neutral
MACD (12,26,9)
0.08
Hist 0.00
ATR (14)
0.27
6.26% of price
Realised vol 30D
69.9%
Annualised
Bollinger upper
4.62
20, 2σ
Bollinger lower
3.70
20, 2σ
50 / 200 cross
Golden
4.06 vs 3.85
Trend bias
Above 200
+11.34%
Risk profile
Beta vs SPY
1.95
More volatile than market
Correlation to SPY
0.26
Largely independent
Realised vol 30D
69.9%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-43.6%
Peak to trough
Max drawdown 5Y
-96.3%
Peak to trough
ATR 14
0.27
6.26% of price
Beta (reported)
—
5Y monthly, from filing
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Ironwood (IRWD) Q2 2026 Earnings Call Transcript
Motley Fool · 9d ago
Ironwood Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
Moby · 15d ago
Ironwood Pharmaceuticals (IRWD) Is Up 14.2% After Raising 2026 Revenue Guidance – Has The Bull Case Changed?
Simply Wall St. · 16d ago
Ironwood Pharmaceuticals Inc (IRWD) (Q2 2026) Earnings Call Highlights: Strong LINZESS Growth ...
GuruFocus.com · 16d ago
Ironwood Pharmaceuticals Q2 Earnings Call Highlights
MarketBeat · 16d ago
Ironwood Pharmaceuticals (IRWD) Q2 Earnings Top Estimates
Zacks · 16d ago
Ironwood: Q2 Earnings Snapshot
Associated Press · 16d ago
Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results
Business Wire · 16d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.